Masimo appointed Katie Szyman as its next chief executive officer and named current interim CEO Michelle Brennan as the new chair of the board. The medical technology company on Tuesday said that the ...

Masimo Corporation (NASDAQ:MASI), a medical technology company valued at $9.36 billion, reported on Friday the resignation of board member Robert Chapek. The departure is set to take effect on the ...

Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO. The Irvine-based medical device maker last week announced ...

Learn more about whether Masimo Corporation or UFP Technologies, Inc. is a better investment based on AAII's A+ Investor ...

Szyman led Edwards Lifesciences’ critical care unit for more than a decade before BD acquired the group last year. Her ...

Learn more about whether ICU Medical, Inc. or Masimo Corporation is a better investment based on AAII's A+ Investor grades, ...

Masimo Co. (NASDAQ:MASI – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven brokerages ...

IRVINE, Calif.--(BUSINESS WIRE)--Today the Board of Directors (the “Board”) of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief ...

The Financial Times reports today that an activist investor wants BD (NYSE:BDX) to sell off its Life Sciences business unit.

BTIG analyst Marie Thibault reiterated a Buy rating on Masimo (MASI – Research Report) today and set a price target of $178.00. The company’s ...

Piper Sandler analyst Jason Bednar maintained a Buy rating on Masimo (MASI – Research Report) today and set a price target of $210.00. The ...

Masimo Corp. today announced Katie Szyman as its new chief executive, effective Feb. 12. Szyman is currently worldwide president of BD Advanced Patient Monitoring, the former Critical Care unit of ...